XOM currently has 3.8 Billion treasury shares they have accumulated through the stock buy back programs over the years. At a price of $79 per share this translates to a value of 300 Billion dollars. There current market cap is 330 Billion dollars so treasury shares represent 91 percent of the Wall Street valuation. Saying thi another way they could buy another company or companies equal to 91 percent of there current value.
Look for XOM to purchase other companies or a Chevron sized company sometime this year as good values created by the low price of oil become even better values.
You and that moron Jeremy sing the same old tired song. Exxon is toast, the sky is falling, get out now, how can anyone invest in a has been company, dividends suck, blah, blah, blah. Your idea of long term is next week and can't see the use of a long term view on anything. I'm putting you both on ignore because I'm tired of your rants. I suggest you both educate yourselves.
Believe me. Exxon would not compromise their 25 years of continuous increases and they are at only 60% of cash flow with the current dividend. Look for a small increase in May of this year.
I know there are other investments I could make that may be better in the short term but I need to consider the tax implications of selling the shares in XOM, some of which I bought at $3 based on the stock splits since the late 70's. No need for you to educate me on investing but I appreciate your concern over my well being.
When you can't refute the facts you resort to insults. I may be a lot older than you but I'm definitely a whole lot wiser. I've made very good investment decisions you can't even dream about. So go ahead and focus on my age while I continue to collect dividends from a stock investment I made decades ago in a company that will be around longer than your sorry #$#$.
Yes I lost a great opportunity by not buying Apple in 1980. You obviously don't remember that Apple almost went bankrupt after their IPO and I doubt you would have held on through that period. I held on to the XOM I started buying in 1979 and am still holding. I'm very happy with my investment, thank you very much.
I'm surprised you didn't mention Berkshire Hathaway in your rant; it was a better investment if you had bought it in 1964. You would have probably bought Kodak. You folks all sound alike.
A very positive article today in the WSJ about ExxonMobil. The big takeaway I found very interesting is that since 1970 XOM has been through 4 boom and bust cycles and ALWAYS recovers. An investment of $100 in XOM in 1970 is now worth $33,000 including dividends and appreciation. Also XOM has increased dividends for 25 years in a row. Look for another increase in the 2nd. quarter report. What's not to like!
This guy Koop... must not have anything else to do with his time. He's responsible for 90% of the posts this morning and it's all garbage. I assume he's trying to overwhelm the board and shout down all the intelligent posts. However he can't change the facts which point decidedly towards good data. Why in the world does he even bother; very annoying. I have had him on ignore for weeks but his post headings keep popping up whenever you access the message board.
I'm holding 2 pair and the other players are betting heavily. Are they bluffing to get me to drop out or do they have 3 of a kind. The pot has been increasing in value and I have been adding to it with each round of betting. Do I fold and cut my losses or do I believe in my hand and stick it out. With the announcement imminent I will play out the hand and see what develops.
There have been no negative press releases from THLD over the last 2 years and every conference in which they have participated they have presented good news. They don't really need the $50 million at this point based on their existing cash amount so I question whether it is really Cowen that is selling new shares to raise money for THLD. Just doesn't make any sense.
I think you hit the nail on the head. Selicks team, by visiting all the sites where the patients have been tested, cannot help but have a general idea of how the overall survival rates are trending and the issuance of a definitive co promotion agreement indicates a high level of confidence that the data will be good. This is beginning to look very encouraging!
The latest presentation just concluded. The major takeaway for me was that both Phase III trial event completions have occurred and Threshold has been traveling to all the various sites to verify the data is clean and acceptable. This is a normal occurance prior to evaluating the final data readouts. Once they are satisfied that all the data sites have yielded clean data it will only take THLD a few minutes to compile it and reach their publishable results. Still forecast for both sets of Phase III data to be released by the end of the year.
Under the terms of the agreement, Merck will receive co-development rights, exclusive global commercialization rights and will provide Threshold an option to co-commercialize the therapeutic in the United States. In exchange, Threshold will receive an upfront payment of $25 million and could receive up to $35 million in additional development milestones during 2012. Threshold is also eligible to receive a $20 million milestone payment based on positive results from its randomized Phase 2 trial in pancreatic cancer. Total potential milestone payments are $525 million, comprised of $280 million in regulatory and development milestones and $245 million in sales-based milestones.
In the United States, Threshold will have primary responsibility for development of TH-302 in the soft tissue sarcoma indication. Threshold and Merck KGaA will jointly develop TH-302 in all other cancer indications being pursued. Merck KGaA will pay 70% of worldwide development costs for TH-302.
Subject to FDA approval in the United States, Merck KGaA will initially be responsible for commercialization of TH-302 with Threshold receiving a tiered, double-digit royalty on sales. Under the royalty-bearing portion of the agreement, Threshold retains the option to co-promote TH-302 in the United States. Additionally, Threshold retains the option to co-commercialize TH-302 allowing the company to participate in up to 50% of the profits in the United States based on certain revenue tiers. Outside of the United States, Merck KGaA will be solely responsible for the commercialization of TH-302 with Threshold receiving a tiered, double-digit royalty on sales in these territories.
From the March 2015 Edison Research Report:
STS 18,000 patients times $80,000 per patient equals $1.44 billion in SALES (not market cap)
Pancreatic Cancer Evo's share of patients is 78,000 times 50% or 39,000
times $80,000 per patient equals $ 3.5 billion in SALES
Total SALES equals $4.94 billion
Assuming 80 million outstanding shares after all warrants are exercised yields a price per share of $370 based on a price to sales ratio of 6.
All this assumes both Phase III tests are approved and does not include any other indications.
Google Edison Research Report for Threshold Pharmaceutical. Then click appropriate location to download full report. Very interesting reading.